Breaking: Five Prime Therapeutics (NASDAQ:FPRX) Buy Rating Reaffirmed by Analysts at Jefferies Today; The Price Objective is Set to $52.0

September 17, 2017 - By Clifton Ray

 Breaking: Five Prime Therapeutics (NASDAQ:FPRX) Buy Rating Reaffirmed by Analysts at Jefferies Today; The Price Objective is Set to $52.0

Investors sentiment decreased to 0.74 in 2016 Q4. Its down 0.41, from 1.15 in 2016Q3. It dived, as 19 investors sold Five Prime Therapeutics Inc shares while 69 reduced holdings. 16 funds opened positions while 49 raised stakes. 24.63 million shares or 4.67% less from 25.83 million shares in 2016Q3 were reported.

Adage Ptnrs Gru Ltd Liability reported 1.90M shares stake. New York State Teachers Retirement Systems stated it has 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). The Massachusetts-based Wellington Grp Ltd Liability Partnership has invested 0.03% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Envestnet Asset Mngmt invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Ny State Common Retirement Fund accumulated 0% or 39,400 shares. Nelson Roberts Investment Advisors Lc reported 0.01% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). California-based Wcm Inv Mngmt Ca has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Advisory Incorporated has 0.02% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX). Assetmark Inc holds 0% or 18 shares in its portfolio. Switzerland-based Swiss Commercial Bank has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Guggenheim Cap Limited Liability Corporation, Illinois-based fund reported 48,938 shares. 89,769 are owned by Goldman Sachs Group Inc Inc. Rock Springs Cap Mngmt Limited Partnership holds 164,000 shares. Mufg Americas owns 376 shares or 0% of their US portfolio. Hbk Invs Ltd Partnership has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 8,018 shares.

Five Prime Therapeutics (NASDAQ:FPRX) Rating Reaffirmed

Equities researchers at Jefferies now has a $52.0 target on Five Prime Therapeutics (NASDAQ:FPRX). Jefferies and their recent target suggests a potential upside of 45.21 % from the company’s stock close price. The rating has been revealed to clients and investors in a research report on Monday morning.

Investors sentiment decreased to 0.74 in 2016 Q4. Its down 0.41, from 1.15 in 2016Q3. It dived, as 19 investors sold Five Prime Therapeutics Inc shares while 69 reduced holdings. 16 funds opened positions while 49 raised stakes. 24.63 million shares or 4.67% less from 25.83 million shares in 2016Q3 were reported.

Adage Ptnrs Gru Ltd Liability reported 1.90M shares stake. New York State Teachers Retirement Systems stated it has 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). The Massachusetts-based Wellington Grp Ltd Liability Partnership has invested 0.03% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Envestnet Asset Mngmt invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Ny State Common Retirement Fund accumulated 0% or 39,400 shares. Nelson Roberts Investment Advisors Lc reported 0.01% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). California-based Wcm Inv Mngmt Ca has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Advisory Incorporated has 0.02% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX). Assetmark Inc holds 0% or 18 shares in its portfolio. Switzerland-based Swiss Commercial Bank has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Guggenheim Cap Limited Liability Corporation, Illinois-based fund reported 48,938 shares. 89,769 are owned by Goldman Sachs Group Inc Inc. Rock Springs Cap Mngmt Limited Partnership holds 164,000 shares. Mufg Americas owns 376 shares or 0% of their US portfolio. Hbk Invs Ltd Partnership has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 8,018 shares.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Among 9 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Five Prime Therapeutics has $5500 highest and $33 lowest target. $44.17’s average target is 23.35% above currents $35.81 stock price. Five Prime Therapeutics had 15 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, September 11 by Jefferies. The rating was maintained by Jefferies with “Buy” on Wednesday, June 7. The company was initiated on Friday, July 31 by Citigroup. Oppenheimer maintained Five Prime Therapeutics Inc (NASDAQ:FPRX) on Monday, October 19 with “Outperform” rating. Credit Suisse initiated the shares of FPRX in report on Thursday, January 21 with “Outperform” rating. BMO Capital Markets initiated the stock with “Market Perform” rating in Tuesday, April 12 report. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Outperform” rating given on Friday, March 11 by Credit Suisse. On Tuesday, August 11 the stock rating was upgraded by Zacks to “Sell”. The firm has “Sell” rating given on Friday, August 21 by Zacks. BMO Capital Markets maintained Five Prime Therapeutics Inc (NASDAQ:FPRX) on Monday, June 5 with “Hold” rating.

The stock increased 1.94% or $0.68 on September 15, reaching $35.81. About 1.21M shares traded or 296.22% up from the average. Five Prime Therapeutics Inc (NASDAQ:FPRX) has declined 30.56% since September 17, 2016 and is downtrending. It has underperformed by 47.26% the S&P500.

Analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to report $-1.32 EPS on November, 2.They anticipate $0.60 EPS change or 83.33 % from last quarter’s $-0.72 EPS. After having $-1.58 EPS previously, Five Prime Therapeutics Inc’s analysts see -16.46 % EPS growth.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The company has market cap of $1.03 billion. The Company’s product candidates include Cabiralizumab , which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. It currently has negative earnings.

More notable recent Five Prime Therapeutics Inc (NASDAQ:FPRX) news were published by: Globenewswire.com which released: “Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics” on September 14, 2017, also Fiercebiotech.com with their article: “Five Prime cuts loose from InhibRx immuno-oncology deal” published on August 29, 2017, Globenewswire.com published: “Five Prime Welcomes Garry Nicholson to Board of Directors” on May 15, 2017. More interesting news about Five Prime Therapeutics Inc (NASDAQ:FPRX) were released by: Nasdaq.com and their article: “Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic …” published on September 10, 2017 as well as Seekingalpha.com‘s news article titled: “Five Prime Therapeutics’ (FPRX) CEO Rusty Williams on Q2 2017 Results …” with publication date: August 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: